CD274 and cancer: The inhibition of PD-1/PD-L1 interactions, through anti-PD1 or anti-PD-L1 monoclonal antibodies, is able to reactivate immune response against cancer and has profoundly changed the treatment of several tumors, including gastric cancer, especially in the metastatic phase [77].